Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Sell

Exponential Moving Average

Strong Sell

Relative Strength Index

Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Neutral

B

Pharvaris N.V. Ordinary Shares (PHVS)

https://www.pharvaris.com

Pharvaris NV is a clinical-stage company. It is focused on the discovery and development and commercialization of therapies for rare diseases with significant unmet need, initially focused on angioedema and other bradykinin-mediated diseases.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

02/05/2021

Market Cap

1,019,557,382

Shares Outstanding

40,860,000

Weighted SO

52,108,675

Total Employees

N/A

Upcoming Earnings

08/05/2024

Similar Tickers

PMVP --.--%

ELYM --.--%

MNOV --.--%

PEPG --.--%

MOLN --.--%

MLYS --.--%

ANTX --.--%

GLUE --.--%

DSGN --.--%

Beta

-3.1030

Last Div

0.0000

Range

15.0-33.0

Chg

-0.2450

Avg Vol

61946

Mkt Cap

1019557382

Exch

NASDAQ

Country

NL

Phone

31 71 203 6410

DCF Diff

7.7944

DCF

11.2056

Div Yield

0.0000

P/S

0.0000

EV Multiple

-6.5775

P/FV

2.5780

Div Yield %

0.0000

P/E

-11.1840

PEG

0.8463

Payout

0.0000

Current Ratio

20.5255

Quick Ratio

20.1267

Cash Ratio

20.0660

DSO

0.0000

DIO

10178.7474

Op Cycle

0.0000

DPO

7726.8539

CCC

0.0000

Gross Margin

0.0000

Op Margin

0.0000

Pretax Margin

0.0000

Net Margin

0.0000

Eff Tax Rate

-0.0146

ROA

-0.2193

ROE

-0.3094

ROCE

-0.2368

NI/EBT

1.0146

EBT/EBIT

0.9593

EBIT/Rev

0.0000

Debt Ratio

0.0005

D/E

0.0005

LT Debt/Cap

0.0002

Total Debt/Cap

0.0005

Int Coverage

-3235.9713

CF/Debt

-476.1409

Equity Multi

1.0513

Rec Turnover

0.0000

Pay Turnover

0.0472

Inv Turnover

0.0359

FA Turnover

0.0000

Asset Turnover

0.0000

OCF/Share

-1.6851

FCF/Share

-1.6870

Cash/Share

6.8444

OCF/Sales

0.0000

FCF/OCF

1.0011

CF Coverage

-476.1409

ST Coverage

-752.8268

CapEx Coverage

-904.7636

Div&CapEx Cov

-904.7636

P/BV

2.5780

P/B

2.5780

P/S

0.0000

P/E

-11.1840

P/FCF

-10.1991

P/OCF

-10.2104

P/CF

-10.2104

PEG

0.8463

P/S

0.0000

EV Multiple

-6.5775

P/FV

2.5780

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jan 22, 06:50 Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks GlobeNewswire Inc. Jan 05, 06:50 Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Dec 08, 18:00 Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023 Benzinga Dec 06, 14:45 Gold Moves Higher; Campbell Soup Earnings Top Expectations Benzinga Dec 06, 14:43 Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session GlobeNewswire Inc. Dec 06, 06:50 Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks GlobeNewswire Inc. Nov 30, 06:50 Pharvaris to Present at the GA²LEN UCARE Conference 2023 GlobeNewswire Inc. Nov 15, 06:50 Pharvaris Appoints Stefan Abele, Ph.D., as Chief Technical Operations Officer GlobeNewswire Inc. Nov 02, 06:50 Pharvaris Reports Third Quarter 2023 Financial Results and Provides Business Update GlobeNewswire Inc. Oct 30, 06:50 Pharvaris To Present at the ACAAI 2023 Annual Scientific Meeting

Revenue Product Segmentation